Loading stock data…
$0.26-0.00 (-1.21%)
IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia.
IGC Pharma, Inc. in the Healthcare sector is trading at $0.26 with a market capitalization of $28M. Wall Street consensus targets $6.00 (1 analysts), implying a +2191.8% move over the next 12 months. The stock is currently near its 52-week low of $0.24, remaining 6.5% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 25 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | — | $317,000↓ | $350,000↑ | $191,000↓ | $328,000 |
| Gross Profit | — | $55,000↑ | $44,000↓ | $99,000↓ | $154,000 |
| Operating Income | — | -$2.46M↑ | -$2.94M↓ | -$2.90M↓ | -$1.91M |
| Net Income | — | -$2.40M↓ | -$726,000↑ | -$1.82M↓ | -$1.60M |
IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead p...